Natus Medical Inc (BABY) Files 10-K for the Fiscal Year Ended on December 31, 2018
GuruFocus.com
- By insider
Natus Medical Inc (BABY) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Natus Medical Inc provides newborn care, neurology healthcare products and services used for screening, diagnosis, detection, treatment, monitoring and tracking of medical ailments in newborn care, epilepsy, and balance and mobility disorders. Natus Medical Inc has a market cap of $954.670 million; its shares were traded at around $28.26 with and P/S ratio of 1.79. Natus Medical Inc had annual average EBITDA growth of 10.50% over the past ten years.
Warning! GuruFocus has detected 3 Warning Signs with BABY. Click here to check it out.
BABY 15-Year Financial Data
The intrinsic value of BABY
Peter Lynch Chart of BABY
For the last quarter Natus Medical Inc reported a revenue of $141.0 million, compared with the revenue of $131.4 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $530.9 million, an increase of 6% from last year. For the last five years Natus Medical Inc had an average revenue growth rate of 9.6% a year.
The reported loss per diluted share was 69 cents for the year. The Natus Medical Inc had an operating margin of 2.39%, compared with the operating margin of 1.92% a year before. The 10-year historical median operating margin of Natus Medical Inc is 8.71%. The profitability rank of the company is 6 (out of 10).
At the current stock price of $28.26, Natus Medical Inc is traded at 22.3% discount to its historical median P/S valuation band of $36.39. The P/S ratio of the stock is 1.79, while the historical median P/S ratio is 2.27. The stock lost 11.3% during the past 12 months.
For the complete 20-year historical financial data of BABY, click here.
This article first appeared on GuruFocus.